CA00288U1066 - Common Stock - After market: 10.96 -0.01 (-0.09%)
NASDAQ:ABCL (2/6/2023, 7:00:00 PM)-0.21 (-1.88%)
GICS Sector | Health Care | ||
GICS Industry | Life Sciences Tools & Services |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-08 2022-11-08/amc | Earnings (Next) | 02-21 2023-02-21/amc |
Ins Owners | 20.37% | Inst Owners | 48.58% |
Market Cap | 3.14B | Shares | 286.10M |
PE | 13.89 | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 83.75 |
IPO | 12-11 2020-12-11 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The firm partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
ABCELLERA BIOLOGICS INC
2215 Yukon Street
Vancouver BRITISH COLUMBIA
P: 16045599005.0
Employees: 386
Website: https://www.abcellera.com/
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
Eli Lilly (LLY) fell in the pre-market Thursday after reporting lower than expected revenue for Q4 2022 as demand for its COVID-19 therapy continued to plunge. Read the full story here.
Here you can normally see the latest stock twits on ABCL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: